CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse (NCT00003673)
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
Phase II trial to study the effectiveness of the antibody-drug conjugate gemtuzumab ozogamicin (also known as CMA-676) (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) in treating older patients who have acute myeloid leukemia that has recurred for the first time following at least 3 months of complete remission.
This trial is sponsored by Pfizer. 
- Condition: Leukemia
- Phase: II
- Estimated Enrollment: 55
- Start: March 1998
- Completion: March 1999
- Last verified: August 2012
Last Editorial review: July 23, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.